Finerenone is a potent and selective nsMRA that blocks MR overactivation andinhibits expression of proinflammatory and profibrotic mediators, includingthose associated with CKD progression.75, , , -79 Recently 2 pivotal trialsexamining cardiorenal endpoints and safety of finerenone in addition to RAASinhibitors in people with DKD were published. Here, NR3C2 is linked to diabetic kidney disease.